BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...with chemotherapy. Other notable additions to the NRDL include HCV drugs Epclusa sofosbuvir/velpatasvir and Harvoni sofosbuvir/ledipasvir...
BioCentury | Apr 26, 2019
Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

...a lower cost authorized alternative instead of a branded product from a manufacturer (see "Epclusa, Harvoni...
BioCentury | Mar 26, 2019
Company News

Louisiana picks Gilead's generics unit for HCV subscription model

...its Asegua Therapeutics LLC subsidiary in 2018 to offer generic versions of Epclusa and Harvoni sofosbuvir/ledipasvir...
...with a wholesale acquisition cost (WAC) of $74,760 for branded Epclusa and $94,500 for branded Harvoni...
BioCentury | Mar 5, 2019
Company News

Lilly offers cheaper insulin, pressuring competitors

...Sciences Inc. (NASDAQ:GILD) announced in September authorized generics for HCV drugs Epclusa sofosbuvir/velpatasvir and Harvoni sofosbuvir/ledipasvir...
BioCentury | Feb 22, 2019
Company News

Subscription payment model for HCV drugs will reduce costs in Australia

...A$9,595 ($7,352). The paper said the U.S. pays $72,765 per patient over five years for Harvoni...
BioCentury | Jan 12, 2019
Finance

We all fall down

...to treat HER2-positive breast cancer Gilead Sciences Inc. (NASDAQ:GILD) China’s National Medical Products Administration approves Harvoni...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...generics and biosimilars. Sales of some Gilead Sciences Inc. (NASDAQ:GILD) antiviral products, such as Harvoni sofosbuvir/ledipasvir...
...NYSE:JNJ) Odefsey emtricitabine/ rilpivirine/ tenofovir alafenamide $1,106.0 $1,150.0 $1,533.3 39% Gilead Sciences Inc. (NASDAQ:GILD) Harvoni sofosbuvir/ledipasvir...
.../ velpatasvir HCV infection China Australia, Canada, EU, U.S. in 2016 Gilead Sciences Inc. (NASDAQ:GILD) Harvoni...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...the last two years due to declining revenues from HCV blockbusters Sovaldi sofosbuvir and Harvoni sofosbuvir/ledipasvir...
...market access. In 2015, about three months after the launch of its follow-on drug Harvoni sofosbuvir/ledipasvir...
BioCentury | Dec 7, 2018
Clinical News

China approves Descovy, Harvoni, Hemlibra

...new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni...
...Harvoni ledipasvir (GS-5885)/sofosbuvir (GS-7977) Business: Hematology; infectious Sandi Wong Descovy (Brand), emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Harvoni (Brand), GS-7977/GS-5885...
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Harvoni (Brand), GS-7977/GS-5885, sofosbuvir/ledipasvir (Generic), sofosbuvir (GS-7977)/ledipasvir (GS-5885) (Informal), ledipasvir (GS-5885)/sofosbuvir (GS-7977) (Informal), Harvoni...
BioCentury | Dec 4, 2018
Company News

China approves Descovy, Harvoni, Hemlibra

...new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni...
...HIV-1 infection in patients aged 12 and older in combination with other antiretroviral agents, while Harvoni...
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Harvoni (Brand), GS-7977/GS-5885, sofosbuvir/ledipasvir (Generic), sofosbuvir (GS-7977)/ledipasvir (GS-5885) (Informal), ledipasvir (GS-5885)/sofosbuvir (GS-7977) (Informal), Harvoni...
Items per page:
1 - 10 of 222